Coexistence of myasthenia gravis and lichen planus: A case report and systematic review of related case reports from 1971 to 2024
Source : https://pubmed.ncbi.nlm.nih.gov/38883218/
Myasthenia gravis (MG) is an uncommon autoimmune disease, resulting in fatigable muscle weakness in the ocular, bulbar, and respiratory muscles, as well as muscles of the extremities. Lichen planus (LP)...
While the exact pathogenesis of MG, LP, and thymoma co‐occurrence remains elusive, it suggests the possibility of a shared autoimmune mechanism. Various theories have been suggested to explain the association between thymoma and autoimmune disorders or paraneoplastic syndromes due to T lymphocyte dysfunction, genetic predisposition, and...
Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis
Source : https://pubmed.ncbi.nlm.nih.gov/38903526/
Myasthenia Gravis (MG) is a chronic disabling autoimmune disease caused by autoantibodies to the neuromuscular junction (NMJ), characterized clinically by fluctuating weakness and early fatigability of ocular, skeletal and bulbar...
The advances in biological drugs’ research promise to significantly change the therapeutic scenario for MG, since these drugs have the potential to overcome the limitations of conventional non-specific IS therapies and greatly increase therapeutic success.
Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11125447/
Myasthenia gravis (MG) is a rare chronic autoimmune disease caused by the production of autoantibodies against the postsynaptic membrane receptors present at the neuromuscular junction. This condition is characterized by...
This review summarizes the nanodrug delivery systems showing therapeutic potential for the immune dysfunction, skeletal muscle mitochondrial impairment, and ferroptosis seen in MG. The aim of this review was to provide valuable insights into the field of MG drug development and encourage interdisciplinary collaboration to explore nano-sized...
Current state of research on exercise for the treatment of myasthenia gravis: A scoping review
Source : https://pubmed.ncbi.nlm.nih.gov/38458542/
This scoping review provides an overview of the evidence concerning exercise treatment for MG. Key gaps in evidence include a limited number of participants, complex interventions, variability in outcome selection,...
This scoping review provides an overview of the evidence concerning exercise treatment for MG. Key gaps in evidence include a limited number of participants, complex interventions, variability in outcome selection, and insufficient reporting in publications. The promotion of exercise treatment for MG still encounters several obstacles. A...
Telitacicept as a novel treatment for refractory lupus nephritis complicated by podocytic infolding glomerulopathy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959545/
Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they...
This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.